Characteristics and Outcomes of People With Gout Hospitalized Due to COVID-19: Data From the COVID-19 Global
Kanon Jatuworapruk1, Anna Montgomery2, Milena Gianfrancesco2
1Thammasat University, Thailand.
Insights
Hospitalized patients with gout and coronavirus disease 2019 (COVID-19) experienced high rates of ventilation support and death. These findings suggest gout patients hospitalized with COVID-19 may face poor outcomes, especially with comorbidities.
Area of Science:
- Rheumatology
- Infectious Diseases
- Critical Care Medicine
Background:
- Gout is a common inflammatory condition.
- Coronavirus disease 2019 (COVID-19) is a global pandemic.
- Understanding COVID-19 outcomes in specific patient populations is crucial.
Purpose of the Study:
- To describe hospitalized patients with gout diagnosed with COVID-19.
- To characterize the outcomes of these patients.
Main Methods:
- Retrospective analysis of data from the COVID-19 Global Rheumatology Alliance registry.
- Inclusion of patients hospitalized between March 2020 and October 2021.
- Descriptive statistics to analyze demographics, comorbidities, medications, and outcomes.
Main Results:
- 163 gout patients hospitalized with COVID-19 were analyzed.
- Mean age was 63 years, 85% male; common comorbidities included hypertension, cardiovascular disease, and diabetes.
- 68% required ventilatory support; 16% died, with most deaths in patients with multiple comorbidities.
Conclusions:
- Hospitalized gout patients with COVID-19 faced high rates of ventilatory support and mortality.
- Age and comorbidities are associated with poor outcomes in this cohort.
- Gout patients hospitalized for COVID-19 may be at increased risk for adverse events.
Objective:
To describe people with gout who were diagnosed with coronavirus disease 2019 (COVID-19) and hospitalized and to characterize their outcomes.
Methods:
Data on patients with gout hospitalized for COVID-19 between March 12, 2020, and October 25, 2021, were extracted from the COVID-19 Global Rheumatology Alliance registry. Descriptive statistics were used to describe the demographics, comorbidities, medication exposures, and COVID-19 outcomes including oxygenation or ventilation support and death.
Results:
One hundred sixty-three patients with gout who developed COVID-19 and were hospitalized were included. The mean age was 63 years, and 85% were male. The majority of the group lived in the Western Pacific Region (35%) and North America (18%). Nearly half (46%) had two or more comorbidities, with hypertension (56%), cardiovascular disease (28%), diabetes mellitus (26%), chronic kidney disease (25%), and obesity (23%) being the most common. Glucocorticoids and colchicine were used pre-COVID-19 in 11% and 12% of the cohort, respectively. Over two thirds (68%) of the cohort required supplemental oxygen or ventilatory support during hospitalization. COVID-19-related death was reported in 16% of the overall cohort, with 73% of deaths documented in people with two or more comorbidities.
Conclusion:
This cohort of people with gout and COVID-19 who were hospitalized had high frequencies of ventilatory support and death. This suggests that patients with gout who were hospitalized for COVID-19 may be at risk of poor outcomes, perhaps related to known risk factors for poor outcomes, such as age and presence of comorbidity.
More Related Videos
06:35An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
04:50Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Rheumatic Heart Disease III: Medical Management
Acute Pyelonephritis II: Diagnostic Studies and Management
Acute Kidney Injury III: Clinical Manifestations
